SecBot SecBot
424B5 ·Filed May 5, 2026

CYTK

CYTOKINETICS INC
MIXED
Impact 6/10
Horizonweeks Processed6mo ago SEC0001193125-26-206626
Notable filing: 424B5
Actionable Insight ◆ Mixed

Monitor pricing and final share count when the offering prices; the overallotment option could add up to $747.5M total. The positive Q1 launch metrics and ACACIA-HCM data provide fundamental support, but near-term selling pressure from the offering may weigh on the stock.

DirectionMixed
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$74.84
T+0 close · May 5, 2026 · via day close
Latest settled
+3.06%
T+60 · $77.13
Vs SPY
+1.00%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 6 $74.84entry
  2. T+1 · 6mo ago −0.73%α −0.40% · $74.29
  3. T+5 · 6mo ago −0.04%α −1.17% · $74.81
  4. T+20 · 6mo ago −5.52%α −8.30% · $70.71
  5. T+60 · 4mo ago +3.06%α +1.00% · $77.13

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Cytokinetics filed a preliminary prospectus supplement for a $650M common stock offering, underwritten by Morgan Stanley, Goldman Sachs, J.P. Morgan, and Jefferies, with an option for an additional $97.5M. The filing comes on the same day as positive Q1 2026 results showing $4.8M in initial MYQORZO revenue and successful ACACIA-HCM trial results. Proceeds will fund the commercial launch and pipeline advancement, but the offering represents significant dilution.

Key Facts

  • Aggregate public offering price of $650,000,000 for common stock
  • Underwriters have 30-day option to purchase additional $97,500,000 in shares
  • As of March 31, 2026, net tangible book deficit was $(826.6) million, or $(6.65) per share
  • 124,237,823 shares outstanding as of March 31, 2026
  • Proceeds intended for MYQORZO commercial launch, pipeline advancement, and general corporate purposes
  • Directors and executive officers subject to 45-day lock-up agreements
  • Q1 2026 MYQORZO net product revenue of $4.8 million from initial partial quarter
  • Cash and investments of approximately $1.1 billion as of March 31, 2026

Financial Impact

$650 million offering represents approximately 8% dilution at current market cap, with proceeds strengthening cash position for commercialization

dilutioncashshare count

Risk Factors

  • Significant dilution to existing shareholders
  • Execution risk in commercial launch of MYQORZO
  • Potential downward price pressure from at-the-market sales by underwriters
  • Continued cash burn from R&D and commercialization activities

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
85% bullish (27 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
424B5 Filing (Primary)0001193125-26-206626
Document: 0001193125-26-206626-index-headers.html0001193125-26-206626
Document: 0001193125-26-206626-index.html0001193125-26-206626
Document: 0001193125-26-206626.txt0001193125-26-206626

Track record

46 reports on CYTK

Performance horizon

7 of 11 bullish or bearish reports moved the stock their way by T+20. Best: +8.59% at T+20 after the Sep 15, 2026 report. 10 of 11 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $53.76 Now $53.17 −1.10% settles Dec 15
  2. Nov 12, 20264d ago Insider Cluster Neutral 3/10 Entry $56.13 Now $53.17 −5.27% settles Dec 14
  3. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $56.18 Now $53.17 −5.36% settles Dec 9
  4. Nov 9, 20267d ago 144 Neutral 2/10 Entry $56.18 Now $53.17 −5.36% settles Dec 9
  5. Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $55.14 Now $53.17 −3.57% settles Dec 8
  6. Nov 9, 20267d ago Press Release Neutral 4/10 Entry $55.14 Now $53.17 −3.57% settles Dec 8
  7. Nov 4, 202612d ago 8-K Bullish 6/10 No price data
  8. Nov 4, 202612d ago Press Release Neutral 5/10 Entry $55.55 Now $53.17 −4.28% settles Dec 4
  9. Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $63.60 Now $53.17 −16.40% settles Dec 3
  10. Nov 2, 202614d ago Press Release Neutral 3/10 Entry $62.03 Now $53.17 −14.28% settles Dec 1
Showing 10 of 46

US Market Status

Market Closed · Opens Wed (11h 54m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 5, 2026